Bill Berkrot

Exclusive: A four-week hep C cure? Bristol to test drugs with Gilead’s Sovaldi

May 14, 2019 at 6:10 a.m.

By Bill Berkrot NEW YORK (Reuters) - In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination...

Pfizer walks away from $118 billion AstraZeneca takeover fight

August 25, 2021 at 4:34 a.m.

By Ben Hirschler and Bill Berkrot LONDON/NEW YORK (Reuters) - Pfizer abandoned its attempt to buy AstraZeneca for nearly 70 billion pounds ($118 billion) on Monday as a deadline approached...

J&J sees device growth via new products, emerging markets

August 25, 2021 at 5:12 a.m.

(Reuters) - Johnson & Johnson said on Thursday it would file for approvals of more than 30 major products by the end of 2016 as it looks to restore growth...

Roche immuno-oncology drug shows promise against bladder cancer

May 14, 2019 at 6:02 a.m.

By Bill Berkrot (Reuters) - Roche Holding's drug from a closely watched new class of cancer immunotherapies showed promise against advanced bladder cancer in a small, early stage study, according...

Bristol, Merck, Roche immune therapies are cancer meeting focus

May 14, 2019 at 6:02 a.m.

By Bill Berkrot (Reuters) - When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck & Co, Bristol-Myers Squibb Co and Roche Holding AG that...

Biogen, Sobi pledge hemophilia drug donation in developing world

May 14, 2019 at 6:02 a.m.

By Bill Berkrot (Reuters) - Biogen Idec Inc and partner Swedish Orphan Biovitrum AB on Monday said they will donate hemophilia drugs for use in developing nations in quantities large...

Pfizer expected to be patient in face of AstraZeneca rejection

August 25, 2021 at 4:35 a.m.

(Reuters) - Pfizer Inc has already had its takeover overtures rebuffed three times by rival AstraZeneca Plc, but investors in the U.S. drugmaker say it can tolerate a little more...

Valeant, Ackman offer to buy Botox maker Allergan for $47 billion

August 25, 2021 at 4:13 a.m.

(Reuters) - Canada's Valeant Pharmaceuticals International Inc said on Tuesday it and activist investor Bill Ackman made an unsolicited $47 billion bid to buy Botox maker Allergan Inc as it...

Valeant, Ackman offer to buy Botox maker Allergan for $47 billion

May 14, 2019 at 5:56 a.m.

(Reuters) - Canada's Valeant Pharmaceuticals International Inc said on Tuesday it and activist investor Bill Ackman made an unsolicited $47 billion bid to buy Botox maker Allergan Inc as it...

Exclusive: Biogen prices hemophilia drug on par with older therapies

August 25, 2021 at 4:07 a.m.

(Reuters) - Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies...

All Stories